drugset / Trial / NCT02920658

Topical "Non-Aromatic Very Rich in Steranes" (NAVS) Naphthalan for the Treatment of Oral Mucosal Diseases

NCT02920658 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the effectiveness of topical NAVS naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Half of participants with OLP and RAS will receive topical NAVS naphthalan in adhesive paste, while the other half will receive 0.05%-betamethasone dipropionate in adhesive paste. Our hypothesis is that NAVS could be efficient in the treatment of OLP and RAS, with effects comparable to that of topical steroids.

Timeline

Start
2010-12
Primary completion
2013-11
Completion
2013-11

Outcome

Missed primary endpoint

paper No significant differences in terms of OLP clinical signs (p = 0.84, η2 = 0.001) PMID 33831097 ↗

paper no significant differences between the groups in terms of lesion number (at days 3 and 5, p = 0.33 and p = 0.98, respectively) PMID 33831097 ↗

paper No evidence of differences between the two compared interventions was found. PMID 33831097 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject NAVS Naphthalan Unknown — Topical
Comparator betamethasone dipropionate Small molecule 0.05 % Topical